Clinipace Worldwide, a clinical research and development company, has raised $3 million in a private stock offering, according to a filing with the Securities and Exchange Commission.

The company filed the From D on Nov. 17 and declined to disclose what it intended to do with the funds.

Clinipace Worldwide is a clinical research organization that works with pharmaceutical, biotechnology and medical device firms to execute regulatory strategies, optimize clinical development timelines and complete high quality trails.

The company has experience with oncology, nephrology, urology, gastroenterology, nutrition, cardiology, diabetes, immunology, infectious diseases and orthopedic services.

The company is led by CEO Jason Monteleone, who joined the company is October 2017. He has over 20 years of experiences in healthcare and life sciences and was a strategic consultant for Clinipace prior to his role as CEO.

He holds an MBA in finance from the Fox School of Business and Management at Temple University and a BS in business administration from Millersville University of Pennsylvania.

Companies relying on a Reg D exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.

The filing can be found here.